LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi Sells 1,250 Shares

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LivaNova Stock Down 1.2 %

Shares of NASDAQ:LIVN opened at $51.50 on Friday. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a market capitalization of $2.80 billion, a PE ratio of 122.62 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a fifty day moving average of $51.97 and a 200-day moving average of $51.55.

Institutional Investors Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently bought and sold shares of LIVN. Fifth Third Bancorp lifted its holdings in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of LivaNova during the second quarter worth about $88,000. Central Pacific Bank Trust Division acquired a new position in shares of LivaNova in the third quarter worth approximately $178,000. TradeLink Capital LLC bought a new stake in LivaNova in the second quarter valued at approximately $208,000. Finally, Captrust Financial Advisors acquired a new stake in LivaNova during the 3rd quarter valued at approximately $217,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. The Goldman Sachs Group started coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.